Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Feature|Articles|June 14, 2024
- Pharmaceutical Executive: June 2024
- Volume 44
- Issue 6
Pharmaceutical Executive: June 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Beyond the Numbers: Extrapolating Today’s Trends Forwardover 2 years ago
Opposite Spectrumsover 2 years ago
2024 Pharm Exec Top 50 Companiesover 2 years ago
Craig Tooman: Silencing the Distractionsover 2 years ago
Regaining Trust in the Pharma Industryover 2 years ago
Succession Attack Plan: Get Strategic with Your Critical Rolesover 2 years ago
The Healthcare System is Changing—So How Should We Respond?over 2 years ago
Biotech Performance Remains Tethered to Rate Expectationsover 2 years ago
Pharm Exec Exclusive: Mark Cuban Talks Drug PricingAdvertisement
Related to this article
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
3
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
4
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
5